The identification of CCR4 + CD73 + cells as a novel stromal cell type associated with adverse prognosis provides crucial insights for post-operative TACE strategies, potentially revolutionizing HCC patient care. The gene discussed is NT5E; the disease is hepatocellular carcinoma.